Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral allergy syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Oral allergy syndrome. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-005060-18 Sponsor Protocol Number: 2016AL002 Start Date*: 2018-03-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin...
    Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001738 Allergy LLT
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004078-26 Sponsor Protocol Number: 10/143/FRE Start Date*: 2011-11-30
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: A double blind placebo controlled randomised trial to study the effects of birch pollen specific immunotherapy (BP-SIT) on the symptoms of the oral allergy syndrome in adult patients.
    Medical condition: Oral allergy syndrome
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    15.1 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    15.1 10021428 - Immune system disorders 10068355 Oral allergy syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001538-18 Sponsor Protocol Number: 603-PG-PSC-74 Start Date*: 2004-09-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen
    Medical condition: Patients have to suffer from IgE mediated allergic rhinits, rhinoconjunctivitis +/- asthma due to sensitization again birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036019 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000548-29 Sponsor Protocol Number: ADA103575 Start Date*: 2007-05-04
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Mont...
    Medical condition: Persistent asthma and seasonal allergic rhinitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed) FI (Prematurely Ended) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-000994-39 Sponsor Protocol Number: BRD 06/2-D Start Date*: 2008-05-27
    Sponsor Name:Centre Hospitalier Universitaire de Nantes
    Full Title: Evaluation de l'intérêt d'un traitement par hydroquinidine pour la prise en charge des patients atteints d'un syndrome de Brugada à risque rythmique élevé et implantés d'un défibrillateur
    Medical condition: Patients with syndroma of Brugada who have an automatic implantable cardiac defibrillator
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059027 Brugada syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-020693-42 Sponsor Protocol Number: VO68.10 Start Date*: 2010-09-07
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract ...
    Medical condition: Birch pollen allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) SK (Completed) LV (Completed) FI (Completed) CZ (Completed) EE (Completed) LT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001791-20 Sponsor Protocol Number: MEPOCHUSS (protocol version 1.2) Start Date*: 2008-06-30
    Sponsor Name:University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
    Full Title: A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome
    Medical condition: Churg-Strauss-Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009164 Churg Strauss syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-002449-41 Sponsor Protocol Number: PRE-COVID Start Date*: 2020-06-15
    Sponsor Name:ANTONIO ANTELA LOPEZ
    Full Title: Pilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis.
    Medical condition: Patients diagnosed with COVID-19, with positive PCR for SARS-CoV-2, without criteria for hospital admission.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003210-39 Sponsor Protocol Number: SXR001 Start Date*: 2021-11-23
    Sponsor Name:Sixera Pharma
    Full Title: A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-time-in-man (FTIM) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applie...
    Medical condition: Netherton-syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Trial now transitioned) AT (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001385-16 Sponsor Protocol Number: BACTstudy Start Date*: 2019-11-22
    Sponsor Name:Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT)
    Full Title: Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial
    Medical condition: Frequent and chronic tension-type headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015884-15 Sponsor Protocol Number: IMPAACT-P1066 Start Date*: 2011-06-30
    Sponsor Name:The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD
    Full Title: A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmac...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004290-97 Sponsor Protocol Number: ACCILTRA1 Start Date*: 2008-12-19
    Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
    Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle...
    Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001496-20 Sponsor Protocol Number: SMR3438 Start Date*: 2019-05-14
    Sponsor Name:Katairo GmbH
    Full Title: A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt disease
    Medical condition: Stargardt Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000441-38 Sponsor Protocol Number: CPCRA 065 Start Date*: 2005-04-26
    Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
    Medical condition: HIV infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002780-30 Sponsor Protocol Number: 9515 Start Date*: 2022-12-01
    Sponsor Name:Aarhus University Hospital, The Research Clinic for Functional Disorders and Psychosomatics
    Full Title: Efficacy of patient education and duloxetine, alone and in combination, for patients with multiorgan bodily distress syndrome: a partial-factorial randomized controlled trial (the EDULOX-trial)
    Medical condition: Multiorgan Functional somatic disorders (FSD) / bodily disstress syndrome (BDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10041319 Somatization disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006504-32 Sponsor Protocol Number: ACTIV-2d/A5407 Start Date*: 2022-12-15
    Sponsor Name:Shionogi B.V.
    Full Title: A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19
    Medical condition: SARS-CoV-2 infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002869-34 Sponsor Protocol Number: AT-03A-001 Start Date*: 2020-08-11
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004787-20 Sponsor Protocol Number: MED3-201601 Start Date*: 2017-10-11
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over ...
    Medical condition: Patients with resectable advanced stage HNSCC (T1–T4 N0-N2 M0) with intermediate risk (resection margins > 5 mm, no perineural invasion and no extracapsular evasion) for whom definite RT post surge...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 19:08:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA